Successful long-term effects of direct renin inhibitor aliskiren in a patient with atherosclerotic renovascular hypertension
Tóm tắt
A 64-year-old man visited our hospital with complaints of misty vision and ophthalmalgia. On admission, his blood pressure (BP) was high at 220/135 mmHg with no past history of hypertension, and he had choked discs. He was tentatively diagnosed as having idiopathic intracranial hypertension, and was later found to have atherosclerotic unilateral renovascular hypertension (RVH) based upon the extremely high plasma renin activity together with the radiological image tests. On day 3, combined antihypertensive therapies consisting of oral angiotensin II receptor blocker (ARB) and Ca channel blocker (CCB) along with intravenous CCB induced an abrupt BP lowering which led to deterioration of his renal function, progressing into acute kidney injury (AKI). Cessation of the ARB and reduction of the CCB dose ameliorated the AKI-related decline in renal function. On day 17, as he was reluctant to receive surgical intervention, he was treated with a direct renin inhibitor, aliskiren, combined with a half-dose CCB as a maintenance antihypertensive therapy. The therapy has proven not only successful to chronically maintain his renal function but was also capable of controlling his BP in the neighborhood of 130/85 mmHg over a period of 2 years. The present case suggests that the direct renin inhibition with aliskiren can be a safe and useful antihypertensive option to control hypertension and to preserve renal function in patients with atherosclerotic unilateral RVH.
Tài liệu tham khảo
Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan: where are we now? Circ J. 2013;77:2226–31.
Dworkin LD, Cooper CJ. Clinical practice. Renal-artery stenosis. N Engl J Med. 2009;361:1972–8.
Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001;344:431–42.
Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet. 1994;344:237–9.
Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J. 1998;136:913–8.
Tanemoto M. Diagnosis and therapy of atheromatous renal artery stenosis. Clin Exp Nephrol. 2013;17:765–70.
ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953–62.
STAR Study Group. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. J Nephrol. 2003;16:807–12.
CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13–22.
Danser AH. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol. 2007;50:105–11.
Kaur S, Muthuraman A. Therapeutic evaluation of rutin in two-kidney one-clip model of renovascular hypertension in rat. Life Sci. 2016;150:89–94.
Grobe N, Leiva O, Morris M, Elased KM. Loss of prolyl carboxypeptidase in two-kidney, one-clip goldblatt hypertensive mice. PLoS One. 2015;10:e0117899.
McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for atmosphere. Eur J Heart Fail. 2012;14:341–3.
Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199–205.
Li SY, Chen YT, Yang WC, et al. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. BMC Nephrol. 2012. doi:10.1186/1471-2369-13-89.
Moriyama T, Tsuruta Y, Kojima C, et al. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol. 2012;44:841–5.
Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17–24.
Kuriyama S, Yokoyama K, Hara Y, et al. Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Clin Exp Nephrol. 2014;18:821–30.